Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? - Wikidata - awgldk - TriplyDB

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

http://www.wikidata.org/entity/Q35553553

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.Current therapy of myelodysplastic syndromes TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.If It's Not One Thing, It's Another: An Inverse Relationship of Malignancy and Atherosclerotic Disease.IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia Fas-670A>G polymorphism is not associated with an increased risk of acute myeloid leukemia development Immunologic consequences of chemotherapy for acute myeloid leukemia.Programmed death-1 checkpoint blockade in acute myeloid leukemia.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease Th17 and Treg cells in bone related diseases.Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders Natural killer cell immune escape in acute myeloid leukemia.Current strategies in immunotherapy for acute myeloid leukemia.Modulating T regulatory cells in cancer: how close are we?Immunotherapy in acute myeloid leukemia.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.New approaches for the immunotherapy of acute myeloid leukemia.Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Umbilical cord blood graft engineering: challenges and opportunities.Immunotherapy in acute myeloid leukemia.Increased regulatory T cells in acute lymphoblastic leukemia patients.Increased regulatory T cells in acute lymphoblastic leukaemia patients.Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.BMP4 is involved in the chemoresistance of myeloid leukemia cells through regulating autophagy-apoptosis balance.Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia.Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.

P2860

Q26770391-BC2E3128-AA9C-4D60-A54C-BBA877051A36 Q26827079-D7424DAC-11B9-47C9-91DF-2E31D1FE0E85 Q33597774-426127BE-B585-4812-A6E8-1C3D2EDBC619 Q33688517-AEC1945E-F467-4434-B94C-AAE0D6F480AD Q34013796-CF597B37-246A-456E-B577-FFE80C39CE5A Q34320769-B5F84496-E2D7-40F0-981B-026CF905A063 Q34655638-0D899ADD-2ACE-4310-9831-645C0AE38C10 Q34715598-66498F9D-398C-4E89-B0F0-BB7333E455D4 Q35051685-18BAAB3D-C86B-4977-BB3D-122C39B13DF1 Q35637017-EFF1B5A0-1860-43C4-971D-F799AD082085 Q35853686-130F0BF5-DE10-4458-A97E-DE9089041DAA Q35928161-DBA3050A-D6F1-4D58-B011-93610DA2C0F6 Q36478891-DF82FCE1-70F2-4CA6-8C84-55FAED72BA5C Q36652124-A260DD36-F780-47C6-B3A5-D4CF90E16DF0 Q36755491-84B63491-161F-490E-8C04-F947411E1546 Q37065718-F932C42C-19C2-4F92-B17D-D7B98E8BA283 Q37239790-A1307176-AC8D-4359-8DF5-DF27DED6F875 Q37429706-3E1F1972-34DB-4AA1-9B3F-F0F3FD41CF5D Q37517482-F138509E-442A-4BB5-AAA9-2E543F460FF8 Q37697695-F4826270-68D3-40D9-A7C4-1B719071CBDE Q37996816-6DCE1061-E9A8-41DF-BB53-6D48478657A6 Q38068967-BE774E9F-EBB7-4623-B45F-434452AF3F20 Q38097311-4EC38B89-2005-4BD7-AEBE-91563262BFB4 Q38171574-33431D24-B0AC-4122-ADE1-7F8B30C58D2C Q38250205-AA11DB8B-B672-4B28-B0E1-D7AF2E0D98BB Q38269046-BAE21CCA-26D2-49E5-83A9-EFDCF4045572 Q38415206-01A7B42A-CD1F-4ED9-839E-31FB3F9A675B Q38482206-913A35C1-81C1-4854-A7DD-51C02B37D1C7 Q38485334-40931C16-6486-48F2-8469-1E40D614C82C Q38514503-5BF9E185-4B51-4341-B42A-EC119A89423D Q38533606-CE0FFF09-B5C2-4F38-BFFB-C29B10354D6C Q38539663-2680068C-9EFE-468F-9E46-6AA62DEDDA9C Q38747439-1A82DDFD-3021-4E21-84B4-C9BF4204DEFB Q38945605-16F382B6-97DA-45B4-A4D3-83BEC2ACB55C Q39094748-7BB11D94-39D8-40FB-8D97-E3C14ADA7CB8 Q39100783-239B384B-63A4-41B2-90B0-1E9BB0F4E8AC Q39125504-48F1D6E4-0538-4FEF-93ED-579F4BB62C61 Q41273685-D1741B2C-6C36-42ED-878A-8BE0C0942E4B Q41573313-33CEBFAA-CA24-4878-8B35-7A0480CA57A8 Q41593302-9C0E8932-C360-41BF-9BEA-8687D9C541DD

P2860

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

http://www.wikidata.org/entity/Q35553553

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@ast

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@en

type

label

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@ast

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@en

prefLabel

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@ast

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@en

P1433

Q35553553-F130F60A-A9DF-48F5-98AC-841971E4A7E5

P1476

Q35553553-3B6E0A44-7250-47D2-A109-A5F0A3885D4A

P2093

Q35553553-AAAD0A73-58A0-4723-9843-2CD7644CEEE7

Q35553553-C0F5DB69-3871-44DC-AB74-3CD206B92659

Q35553553-C71501AE-D156-4152-9149-9657F2DCE577

Q35553553-EA1D65BF-8143-4769-9D0C-EA9EABD72EE4

P2860

Q35553553-0063D9D1-1775-4E8E-A40A-60EC6032BAB4

Q35553553-06DD2651-09BC-4695-9EE6-25A9E16C3034

Q35553553-0784B0AC-C7DC-4F7D-BBAF-557E00A02F90

Q35553553-07CC6DE7-2D4C-4338-B77D-EC4CB5168B55

Q35553553-09F7062C-1862-4821-809D-A8837BBC3F98

Q35553553-0C6DF0CD-88A2-4C21-8657-93DC0228686F

Q35553553-10379856-9243-479E-BD19-972F9CA482B9

Q35553553-12234E0F-99D0-4462-996B-026BC231EAF9

Q35553553-1521E8E0-BD68-414F-AE4E-B37808A9CEFC

Q35553553-177CBBB0-49F6-4639-82AD-F59678093761

P304

Q35553553-B835E71B-54E0-460C-B6C3-000D49B89D52

P31

Q35553553-9BFA407D-1B2F-4F00-8F2A-ACBD83F746B5

P356

Q35553553-5E6105F1-3D4B-4E83-BAFE-5D7DB2DA5A6D

P407

Q35553553-80D3AFD7-573D-426C-99D1-607EA1ACBBFA

P433

Q35553553-54A69939-F9FA-49EA-A7F4-459278ABEE8D

P478

Q35553553-5D4E4226-4949-4711-8834-F7704896EFE3

P50

Q35553553-FAD9A2C2-E722-4E70-BF45-A77B9504023B

P577

Q35553553-98BBFB5D-0620-43BB-910F-22388874C8EA

P5875

Q35553553-73CAC59D-31D9-40CF-9EF6-249D5E4A273A

P698

Q35553553-A582838C-CA45-4A70-AAB3-8F7DFC516387

P921

Q35553553-76FE574E-36EA-4B72-B2A4-AD444F3DB7BD

P932

Q35553553-1B900FB3-F007-4035-94E2-C8559D52869E

P356

BLOOD-2011-07-365817

P1433

P1476

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

@en

P2093

Celalettin Ustun

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

David H Munn

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression

T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface

Control of regulatory T cell development by the transcription factor Foxp3

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

P304

5084-5095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-365817

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51608743

http://www.w3.org/2001/XMLSchema#string

P698

21881045

http://www.w3.org/2001/XMLSchema#string

P921

P932

3217399

http://www.w3.org/2001/XMLSchema#string